Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLO NASDAQ:BLUE NASDAQ:BOLD NASDAQ:CRSP NASDAQ:HALO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLOAllogene Therapeutics$1.23-3.1%$1.17$0.86▼$3.78$281.79M0.433.44 million shs2.82 million shsBLUEbluebird bio$4.97$4.78$3.20▼$25.10$48.67M0.27452,966 shsN/ABOLDBoundless Bio$1.32-42.6%$59.97$1.00▼$4.72$29.10M-0.97138,670 shs96,520 shsCRSPCRISPR Therapeutics$69.38+1.6%$59.59$30.04▼$78.48$6.21B1.843.01 million shs2.52 million shsHALOHalozyme Therapeutics$66.65+2.0%$71.30$42.01▼$79.50$7.64B1.162.32 million shs2.60 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLOAllogene Therapeutics-3.15%-8.89%+8.85%0.00%-53.23%BLUEbluebird bio0.00%0.00%0.00%0.00%-50.63%BOLDBoundless Bio+1.93%+8.20%+15.79%+16.30%-56.29%CRSPCRISPR Therapeutics+1.60%-1.76%+23.32%+25.83%+45.07%HALOHalozyme Therapeutics+2.02%+0.95%-13.33%+14.89%+23.54%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLOAllogene Therapeutics$1.23-3.1%$1.17$0.86▼$3.78$281.79M0.433.44 million shs2.82 million shsBLUEbluebird bio$4.97$4.78$3.20▼$25.10$48.67M0.27452,966 shsN/ABOLDBoundless Bio$1.32-42.6%$59.97$1.00▼$4.72$29.10M-0.97138,670 shs96,520 shsCRSPCRISPR Therapeutics$69.38+1.6%$59.59$30.04▼$78.48$6.21B1.843.01 million shs2.52 million shsHALOHalozyme Therapeutics$66.65+2.0%$71.30$42.01▼$79.50$7.64B1.162.32 million shs2.60 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLOAllogene Therapeutics-3.15%-8.89%+8.85%0.00%-53.23%BLUEbluebird bio0.00%0.00%0.00%0.00%-50.63%BOLDBoundless Bio+1.93%+8.20%+15.79%+16.30%-56.29%CRSPCRISPR Therapeutics+1.60%-1.76%+23.32%+25.83%+45.07%HALOHalozyme Therapeutics+2.02%+0.95%-13.33%+14.89%+23.54%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLOAllogene Therapeutics 2.54Moderate Buy$8.44586.54% UpsideBLUEbluebird bio 2.17Hold$25.75418.11% UpsideBOLDBoundless Bio 2.00Hold$3.50165.15% UpsideCRSPCRISPR Therapeutics 2.42Hold$71.713.35% UpsideHALOHalozyme Therapeutics 2.38Hold$73.009.53% UpsideCurrent Analyst Ratings BreakdownLatest HALO, ALLO, BLUE, CRSP, and BOLD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/14/2025BOLDBoundless BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/14/2025HALOHalozyme TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderperform ➝ Market Perform$70.0010/13/2025CRSPCRISPR TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$75.0010/10/2025ALLOAllogene TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral ➝ Underweight10/10/2025CRSPCRISPR TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$81.0010/8/2025ALLOAllogene TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025BOLDBoundless BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025CRSPCRISPR TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025HALOHalozyme TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C+) ➝ Buy (B-)10/6/2025HALOHalozyme TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold10/2/2025HALOHalozyme TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$85.00 ➝ $90.00(Data available from 10/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLOAllogene Therapeutics$20K13,645.62N/AN/A$2.01 per share0.61BLUEbluebird bio$103.95M0.47N/AN/A$35.59 per share0.14BOLDBoundless BioN/AN/AN/AN/A$6.76 per shareN/ACRSPCRISPR Therapeutics$37.31M169.13N/AN/A$22.64 per share3.06HALOHalozyme Therapeutics$1.02B7.68$4.75 per share14.04$2.86 per share23.30Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLOAllogene Therapeutics-$257.59M-$1.11N/AN/AN/AN/A-55.99%-42.75%11/6/2025 (Estimated)BLUEbluebird bio-$211.91M-$41.32N/AN/AN/A-565.74%-322.46%-53.17%N/ABOLDBoundless Bio-$65.36MN/AN/AN/AN/AN/A-44.79%-34.24%N/ACRSPCRISPR Therapeutics-$366.25M-$5.43N/AN/AN/A-1,229.43%-20.05%-17.09%11/4/2025 (Estimated)HALOHalozyme Therapeutics$444.09M$4.3715.2510.720.3547.28%150.85%29.19%10/30/2025 (Estimated)Latest HALO, ALLO, BLUE, CRSP, and BOLD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025ALLOAllogene Therapeutics-$0.23N/AN/AN/AN/AN/A11/4/2025Q3 2025CRSPCRISPR Therapeutics-$1.32N/AN/AN/A$8.74 millionN/A10/30/2025Q3 2025HALOHalozyme Therapeutics$1.63N/AN/AN/A$339.18 millionN/A8/13/2025Q2 2025ALLOAllogene Therapeutics-$0.28-$0.23+$0.05-$0.23N/AN/A8/5/2025Q2 2025BOLDBoundless Bio-$0.75-$0.70+$0.05-$0.70N/AN/A8/5/2025Q2 2025HALOHalozyme Therapeutics$1.23$1.54+$0.31$1.33$282.66 million$325.72 million8/4/2025Q2 2025CRSPCRISPR Therapeutics-$1.47-$1.29+$0.18-$2.40$6.44 million$0.89 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALLOAllogene TherapeuticsN/AN/AN/AN/AN/ABLUEbluebird bioN/AN/AN/AN/AN/ABOLDBoundless BioN/AN/AN/AN/AN/ACRSPCRISPR TherapeuticsN/AN/AN/AN/AN/AHALOHalozyme TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLOAllogene TherapeuticsN/A8.928.92BLUEbluebird bio0.370.510.33BOLDBoundless Bio0.3914.0814.08CRSPCRISPR TherapeuticsN/A16.6116.61HALOHalozyme Therapeutics4.548.367.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLOAllogene Therapeutics83.63%BLUEbluebird bio87.43%BOLDBoundless BioN/ACRSPCRISPR Therapeutics69.20%HALOHalozyme Therapeutics97.79%Insider OwnershipCompanyInsider OwnershipALLOAllogene Therapeutics13.20%BLUEbluebird bio1.40%BOLDBoundless Bio21.10%CRSPCRISPR Therapeutics4.10%HALOHalozyme Therapeutics2.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLOAllogene Therapeutics310221.88 million192.59 millionOptionableBLUEbluebird bio5209.79 million9.59 millionOptionableBOLDBoundless Bio20722.39 million17.66 millionNo DataCRSPCRISPR Therapeutics46090.95 million87.22 millionOptionableHALOHalozyme Therapeutics390116.97 million113.57 millionOptionableHALO, ALLO, BLUE, CRSP, and BOLD HeadlinesRecent News About These CompaniesHalozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Rating of "Hold" by Brokerages1 hour ago | americanbankingnews.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Receives Average Rating of "Hold" from Analysts1 hour ago | marketbeat.comHalozyme Therapeutics (NASDAQ:HALO) Raised to Market Perform at Leerink PartnersOctober 14 at 2:19 PM | marketbeat.comHalozyme Announces Merger Agreement with ElektrofiOctober 14 at 2:17 PM | theglobeandmail.comHalozyme Confirms Minimal Impact from Medicare GuidanceOctober 14 at 7:31 AM | tipranks.comJanney Montgomery Scott LLC Sells 269,655 Shares of Halozyme Therapeutics, Inc. $HALOOctober 13 at 4:21 AM | marketbeat.comOak Ridge Investments LLC Trims Holdings in Halozyme Therapeutics, Inc. $HALOOctober 12 at 5:45 AM | marketbeat.comCastellan Group Has $832,000 Stock Position in Halozyme Therapeutics, Inc. $HALOOctober 11, 2025 | marketbeat.comWhat is Zacks Research's Forecast for HALO Q3 Earnings?October 11, 2025 | americanbankingnews.comStrong And Rising: Halozyme Therapeutics Stock May Have More UpsideOctober 10, 2025 | forbes.comZacks Research Issues Negative Estimate for HALO EarningsOctober 10, 2025 | marketbeat.comTectonic Advisors LLC Decreases Holdings in Halozyme Therapeutics, Inc. $HALOOctober 10, 2025 | marketbeat.comQ1 EPS Estimate for Halozyme Therapeutics Raised by AnalystOctober 10, 2025 | americanbankingnews.comHalozyme Therapeutics (NASDAQ:HALO) Upgraded by Weiss Ratings to "Buy (B-)" RatingOctober 9, 2025 | marketbeat.comCan Elektrofi Acquisition Drive Halozyme's Long-Term Growth?October 8, 2025 | zacks.comHalozyme Therapeutics (NASDAQ:HALO) Downgraded by Zacks Research to HoldOctober 8, 2025 | marketbeat.comZacks Research Analysts Increase Earnings Estimates for HALOOctober 8, 2025 | marketbeat.comHalozyme Therapeutics (HALO): What Recent Gains Reveal About Its Current ValuationOctober 8, 2025 | finance.yahoo.comHalozyme names Cortney Caudill as COOOctober 7, 2025 | msn.comHalozyme Appoints New Chief Operating OfficerOctober 7, 2025 | msn.comHalozyme Appoints New Chief Operating OfficerOctober 7, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?By Thomas Hughes | September 18, 2025Vertical Aerospace Presents Its Blueprint for Sector LeadershipBy Jeffrey Neal Johnson | September 23, 2025Treat Your Portfolio With These 3 Spooky Season StocksBy Nathan Reiff | October 8, 2025Applied Digital’s Shorts Got Squeezed—Now What?By Thomas Hughes | October 13, 2025HALO, ALLO, BLUE, CRSP, and BOLD Company DescriptionsAllogene Therapeutics NASDAQ:ALLO$1.23 -0.04 (-3.15%) Closing price 10/14/2025 04:00 PM EasternExtended Trading$1.23 0.00 (-0.41%) As of 10/14/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.bluebird bio NASDAQ:BLUEbluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.Boundless Bio NASDAQ:BOLDAudentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It is also developing vectorized antisense treatments for the treatment of duchenne muscular dystrophy and myotonic dystrophy type 1. The company has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and a license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. Audentes Therapeutics, Inc. was founded in 2012 and is headquartered in San Francisco, California.CRISPR Therapeutics NASDAQ:CRSP$69.38 +1.09 (+1.60%) Closing price 10/14/2025 04:00 PM EasternExtended Trading$69.80 +0.42 (+0.61%) As of 10/14/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.Halozyme Therapeutics NASDAQ:HALO$66.65 +1.32 (+2.02%) Closing price 10/14/2025 04:00 PM EasternExtended Trading$67.46 +0.81 (+1.22%) As of 10/14/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Healthcare Companies Insiders Are Buying NVIDIA Analysts Lift Targets: What It Means for the Stock Price Fastenal Stock Pulls Back in October—Is It Time to Buy FAST? 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise Why Congress Is Buying Intuitive Surgical Ahead of Earnings D-Wave: Reevaluating the Short Seller’s Case After the Downgrade 3 Dividend Hikes That Signal Renewed Strength in 2025 2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
